Searched for
DIAGNOSTIC CHAIN
A termite pesticide banned in 1988 is still turning up in wildlife; researchers found toxic brain levels in nearly half the sick skunks they examined near DetroitA banned pesticide, chlordane, used for termite control, is causing severe neurological damage and death in urban skunks, according to new ...- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsIt is probably time to be bullish as an investor. But remember two things. One: Valuations are still not cheap. Two: Because it is over and...
- For investors who focus on the long term: 5 mid-cap stocks from different sectors with upside potential up to 28%When prices fall, caution comes naturally. Investors hesitate, portfolios are reviewed less often, and even optimists become careful. But w...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 24%When business updates start to come in or when some FMCG or auto companies indicate that things are not all good in the rural space, we may...
- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- Financials in a sweet spot, defence remains a structural bet: Dharmesh KantFinancial stocks are set to lead a market rally through June and July. Experts see banks and financial institutions benefiting from strong ...
- Karnataka explores biotech financing framework, AI-led innovation to support sector growthKarnataka is developing a dedicated support framework for its biotechnology sector, encompassing funding, mentoring, and regulatory guidanc...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- PMS vs mutual funds: 5 reasons to invest, and 5 red flags to watchPortfolio Management Services (PMS) offer structural advantages over mutual funds, allowing for concentrated portfolios, significant cash h...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 27%, according to analystsWe are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Japanese investors are looking beyond China... India is key alternative: Tsutomu Takemura, Senior MD, NomuraIndia is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...
- Which AI products are actually delivering results? The innovations defining enterprise AI in 2026The AI era has moved from potential to proof. In 2026, the products that matter are not the most complex; they are the ones delivering meas...
- Science at scale: India’s journey from food security to global leadershipToday, India is the world’s largest producer of milk, pulses, and spices; the largest exporter of rice; and among the leading producers of ...
- Clean rules put auto parts cos on a whole new growth pathIndia's auto component sector is set for a growth spurt. New rules for cleaner, safer, and fuel-efficient vehicles are boosting demand for ...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- PE wars to billion-dollar IPO dreams, hospital sector is fighting fitMajor private equity firms are vying for a stake in Cloudnine, a leading maternity and paediatric care chain. This intense competition high...
- Buy financials, healthcare, and manufactured exports; Pramod Gubbi on investing in a tricky marketIndia's Q4 earnings show recovery signs, with Nifty 100 profits up 13%. However, macro headwinds like rising crude oil prices and a depreci...
Load More
